Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 19/20 | 0.86 |
| ▸ | LCK | P06239 | 3/20 | 0.85 |
| ▸ | CSK | P41240 | 2/20 | 0.85 |
| ▸ | ABL1 | P00519 | 2/20 | 0.65 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.65 |
| ▸ | EGFR | P00533 | 1/20 | 0.65 |
| ▸ | HCK | P08631 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.65 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.65 |
| ▸ | MTOR | P42345 | 1/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.65 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.65 |
| ▸ | PRKDC | P78527 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14617312 | 0.93 | SRC (1.00) | SRCLCKCSKABL1PIK3CD | |
| SCHEMBL17962870 | 0.92 | SRC (1.00) | SRCLCKCSKABL1PIK3CD | |
| SCHEMBL14617311 | 0.92 | SRC (1.00) | SRCLCKCSKABL1PIK3CD | |
| SCHEMBL14617296 | 0.86 | SRC (1.00) | SRCLCKCSKABL1PIK3CD | |
| SCHEMBL17962908 | 0.85 | SRC (1.00) | SRCLCKCSKABL1KCNH2 | |
| SCHEMBL12608279 | 0.80 | SRC (1.00) | SRCLCKCSKABL1PIK3CD | |
| SCHEMBL17962907 | 0.79 | SRC (1.00) | SRCLCKCSKABL1KCNH2 | |
| SCHEMBL17962789 | 0.78 | SRC (1.00) | SRCLCKCSKABL1KCNH2 | |
| SCHEMBL29388050 | 0.78 | KCNH2 (1.00) | SRCLCKCSKABL1KCNH2 | |
| SCHEMBL14574638 | 0.78 | KCNH2 (1.00) | SRCLCKCSKABL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350211-B2 | Bumped kinase inhibitor compositions and methods for treating cancer | UNIVERSITY OF WASHINGTON (US) | 2019-07-16 | — | — | US | claimed |
| US-20180273537-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-09-27 | — | — | US | claimed |
| US-20180271871-A1 | BUMPED KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-09-27 | — | — | US | claimed |
| EP-3250290-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | University of Washington (US) | 2017-12-06 | — | — | EP | claimed |
| WO-2016123152-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | UNIVERSITY OF WASHINGTON (US) | 2016-08-04 | — | — | WO | claimed |
| WO-2016123151-A1 | BUMPED KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | UNIVERSITY OF WASHINGTON (US) | 2016-08-04 | — | — | WO | claimed |
| US-10632122-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON (US) | 2020-04-28 | — | — | US | disclosed |
| US-10350211-B2 | Bumped kinase inhibitor compositions and methods for treating cancer | UNIVERSITY OF WASHINGTON (US) | 2019-07-16 | — | — | US | disclosed |
| US-10307425-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180271871-A1 | BUMPED KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-09-27 | — | — | US | disclosed |
| US-20180273537-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-09-27 | — | — | US | disclosed |
| WO-2016123151-A1 | BUMPED KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | UNIVERSITY OF WASHINGTON (US) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273537-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | PNCK, TXK, CAMKK1 | SRC 171/4885LCK 267/4885CSK 32/4885 |
| US-10632122-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | PNCK, TXK, CAMKK1 | SRC 171/4885LCK 267/4885CSK 32/4885 |
| US-20180271871-A1 | BUMPED KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | CHEK2, CHEK1, DCK | SRC 76/4885LCK 140/4885CSK 62/4885 |
| US-10350211-B2 | Bumped kinase inhibitor compositions and methods for treating cancer | CHEK2, CHEK1, DCK | SRC 76/4885LCK 140/4885CSK 62/4885 |
| US-10307425-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | PNCK, CAMKK1, CILK1 | SRC 177/4885LCK 277/4885CSK 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.